معرفی
Dr. David J Welsh serves as an Honorary Research Fellow in the School of Cardiovascular & Metabolic Health at the University of Glasgow, based at the Scottish Pulmonary Vascular Unit within the Department of Biological and Biomedical Sciences. His research is centered at the Charles Oakley Building in Glasgow, where he investigates critical mechanisms in pulmonary vascular diseases.
His primary research focuses on molecular pathways in pulmonary hypertension, particularly vascular remodeling and right ventricular dysfunction. Key interests include p38 MAPK signaling, IL-33/ST2 pathways, fibroblast-endothelial interactions, and therapeutic interventions using agents like macitentan and fluvastatin. His work bridges molecular biology, pharmacology, and clinical imaging to develop novel anti-remodeling strategies.
Analysis of his 15-year publication record reveals consistent exploration of pulmonary hypertension pathogenesis, with emphasis on kinase inhibitors, inflammatory mediators, and vascular cell phenotypes. His research demonstrates translational progression from cellular models to in vivo validation and clinical imaging applications.
Scientific recognition includes:
- Wellcome VIP award (Wellcome Trust, 2010)
Dr. Welsh has secured substantial research funding as principal investigator for projects investigating pulmonary vascular mechanisms:
- IL-33/ST2 signaling in pulmonary arterial hypertension (British Heart Foundation, 2017-2021)
- Mechanisms of pulmonary arterial hypertension development (Medical Research Council, 2013-2018)
- Apelin effects in pulmonary hypertension (British Heart Foundation, 2012-2014)
- Fibroblast roles in vascular remodeling (Wellcome Trust, 2009-2012)
He operates within the Scottish Pulmonary Vascular Unit, a specialized research environment focused on pulmonary vascular pathophysiology and therapeutic innovation.
